Allergy Therapeutics PLC Stock
Price
Target price
€0.13
€0.13
0.780%
0.001
0.780%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Allergy Therapeutics PLC Stock
Allergy Therapeutics PLC gained 0.780% compared to yesterday.
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.780% | 9.402% | 12.281% | 66.234% | 9.402% | 169.474% | -21.231% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 7.143% | 5.727% | 10.092% | 7.143% | -6.796% | -56.757% |
| Eledon Pharmaceuticals Inc. | 0.730% | 7.031% | 3.008% | -68.578% | 7.031% | -46.899% | -88.291% |
| SELLAS Life Sciences Group Inc | -2.600% | 22.222% | 131.000% | 243.069% | 22.222% | 36.579% | -36.469% |
News
3 of the Best Stocks Under $100 to Buy in 2026
Want some good, cheap stocks to buy for the new year? The ones that I've listed below all trade below $100 a share, are cheap with respect to their earnings, and offer a mix of value, dividends, and
Datavault AI and The Dream Bowl to Set New Benchmark in Sports Innovation with World’s First Tokenized Autograph Session, Featuring Current and Future NFL Stars - Live on ESPN+
30 former NFL star players from different NFL Teams will autograph on-site up to 3,000 The Dream Bowl memorabilia items such as helmets, footballs, jerseys, and live-autographs by Notable
Can ASTS Stock Beat the Market in 2026?
AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share